ZYLM (Central Asia Lumeichun Biotechnology) Total Assets: $4.73 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Central Asia Lumeichun Biotechnology Total Assets?

Central Asia Lumeichun Biotechnology ZYLM Total Assets is $4.73 Mil as of Jun. 2026.

Central Asia Lumeichun Biotechnology's Total Assets for the quarter that ended in Jun. 2026 was $4.73 Mil.

Total Assets is connected with ROA %. Central Asia Lumeichun Biotechnology's annualized ROA % for the quarter that ended in Jun. 2026 was -4.27%. Total Assets is also linked to Revenue through Asset Turnover. Central Asia Lumeichun Biotechnology's Asset Turnover for the quarter that ended in Jun. 2026 was 0.07.

Central Asia Lumeichun Biotechnology  (OTCPK:ZYLM) Total Assets Explanation

Total Assets is connected with ROA %.

Central Asia Lumeichun Biotechnology's annualized ROA % for the quarter that ended in Jun. 2026 is

ROA %=Net Income (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=-0.19918/( (4.606818+4.725224)/ 2 )
=-0.19918/4.666021
=-4.27 %

Note: The Net Income data used here is four times the quarterly (Jun. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Central Asia Lumeichun Biotechnology's Asset Turnover for the quarter that ended in Jun. 2026 is

Asset Turnover
=Revenue (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=0.332471/( (4.606818+4.725224)/ 2 )
=0.332471/4.666021
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Central Asia Lumeichun Biotechnology Total Assets Related Terms

Central Asia Lumeichun Biotechnology Total Assets Historical Data

* Premium members only.

The historical data trend for Central Asia Lumeichun Biotechnology's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Asia Lumeichun Biotechnology Total Assets Chart

Central Asia Lumeichun Biotechnology Annual Data
Trend Mar07 Mar08 Mar09 Mar10 Mar11 Mar14 Mar15 Aug23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.18 1.32 2.19 2.00 3.26

Central Asia Lumeichun Biotechnology Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun13 Jun15 Sep15 Dec15 Nov22 Feb23 May23 Aug23 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.96 3.31 3.26 4.61 4.73

Central Asia Lumeichun Biotechnology Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Central Asia Lumeichun Biotechnology's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=1.260703+1.996917
=3.26

Central Asia Lumeichun Biotechnology's Total Assets for the quarter that ended in Jun. 2026 is calculated as

Total Assets=Total Equity (Q: Jun. 2026 )+Total Liabilities (Q: Jun. 2026 )
=1.222613+3.502611
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $4.73 Mil mean?
Central Asia Lumeichun Biotechnology (ZYLM) has a Total Assets of $4.73 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Central Asia Lumeichun Biotechnology and its competitors.
Is Central Asia Lumeichun Biotechnology's Total Assets too high?
Central Asia Lumeichun Biotechnology's current Total Assets is $4.73 Mil.
How does Central Asia Lumeichun Biotechnology's Total Assets compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's Total Assets of $4.73 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Consumer Packaged Goods company?
A good Total Assets depends on the Consumer Packaged Goods industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Central Asia Lumeichun Biotechnology and its competitors. Central Asia Lumeichun Biotechnology's current Total Assets is $4.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current Total Assets of $4.73 Mil. The current Total Assets is $4.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current Total Assets is $4.73 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Asia Lumeichun Biotechnology Business Description

Address Longguan Avenue, Room 1401, Yunhua Building, Longhua District, Shenzhen, CHN
Central Asia Lumeichun Biotechnology Inc is an ecological agriculture company. It operates a sika deer breeding base in southern China.